Continued Intravenous Versus First Week Transition to Oral Antibiotic Therapy in Bloodstream Infections: A Systematic Review and Meta-Analysis.

Bloodstream infections (BSIs) are a major public health concern worldwide, requiring prompt and effective antibiotic therapy. Traditionally, intravenous (IV) antibiotics have been preferred for their rapid action and consistent absorption. However, interest is growing in transitioning to oral (PO) antibiotics when suitable, due to similar pharmacokinetics, improved patient outcomes, and reduced healthcare costs. This meta-analysis aims to evaluate the clinical effectiveness of switching from IV to PO antibiotics for both gram-negative and gram-positive BSIs. Scopus, Embase, and PubMed databases were comprehensively searched until March 2023. The review included randomized controlled trials and cohort studies comparing continued IV therapy with early transition from IV to PO antibiotics within the first week of admission. Inclusion criteria encompassed studies involving adult patients (≥18 years) and reporting specific outcomes such as treatment success, mortality, and hospital readmissions. Meta-analysis of 17 studies comprising 11,245 patients demonstrated higher treatment success rates overall (OR: 1.40, P=0.04), particularly in gram-negative infections (OR: 1.42, P=0.05). However, this effect was not statistically significant in the gram-positive subgroup (OR: 1.41, P=0.036). Oral switch significantly reduced all-cause mortality overall (OR: 0.35, P=0.003), especially in gram-negative infections (OR: 0.22, P=0.008), but not significantly in gram-positive infections (OR: 0.60, P=0.09). Both gram-negative and gram-positive infections benefited from shorter hospital stays (P<0.0001), despite significant heterogeneity. Hospital readmission rates did not significantly differ between IV and oral switch groups (P=0.53). Our meta-analysis suggests potential benefits of early transition from IV to PO antibiotics for BSIs, including improved treatment outcomes and shorter hospital stays without an increased risk of readmission. However, these findings are subject to selection bias, and further standardized randomized trials are essential to validate these results.